$88.50
-0.01-0.01%
À la fermeture: -
$88.50
N/A
Après les heures de négociation: Nov 7, 4:01 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Zimmer Biomet Holdings Inc a un objectif de cours consensuel de $114.04 basé sur les évaluations de 27 analystes. Le plus élevé est $150, publié par Argus Research le mai 21, 2024. Le plus bas est $88, publié par UBS le novembre 6, 2025. Les 3 évaluations d’analystes les plus récentes ont été publiées par UBS, RBC Capital et Barclays le novembre 6, 2025, respectivement. Avec un objectif de cours moyen de $97.67 entre UBS, RBC Capital et Barclays, il existe une variation implicite de 10.36% upside pour Zimmer Biomet Holdings Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
UBS
RBC Capital
Barclays
JP Morgan
BTIG
1calculé à partir des notes des analystes
Notes d'analystes pour Zimmer Biomet Holdings
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | -0.56% | UBS | $96 → $88 | Maintains | Sell | |||
11/06/2025 | 14.12% | RBC Capital | $111 → $101 | Maintains | Outperform | |||
11/06/2025 | 17.51% | Barclays | $105 → $104 | Maintains | Underweight | |||
11/06/2025 | 12.99% | JP Morgan | $115 → $100 | Downgrade | Overweight → Neutral | |||
11/05/2025 | 18.64% | Barclays | $112 → $105 | Maintains | Underweight | |||
11/05/2025 | 26.55% | BTIG | $122 → $112 | Maintains | Buy | |||
10/22/2025 | 14.12% | Canaccord Genuity | $101 → $101 | Maintains | Hold | |||
10/13/2025 | 37.85% | BTIG | $118 → $122 | Maintains | Buy | |||
10/07/2025 | 17.51% | Evercore ISI Group | $106 → $104 | Maintains | In-Line | |||
09/19/2025 | 33.33% | Stifel | $115 → $118 | Maintains | Buy | |||
09/18/2025 | 46.89% | Rothschild & Co | → $130 | Initiates | → Buy | |||
08/08/2025 | 29.94% | RBC Capital | $112 → $115 | Maintains | Outperform | |||
08/08/2025 | 8.47% | UBS | $91 → $96 | Maintains | Sell | |||
08/08/2025 | 27.68% | Raymond James | $104 → $113 | Maintains | Outperform | |||
07/08/2025 | 8.47% | Evercore ISI Group | $102 → $96 | Maintains | In-Line | |||
05/12/2025 | 14.12% | Canaccord Genuity | $115 → $101 | Maintains | Hold | |||
05/07/2025 | 41.24% | JMP Securities | $140 → $125 | Maintains | Market Outperform | |||
05/06/2025 | 17.51% | Goldman Sachs | $120 → $104 | Maintains | Neutral | |||
05/06/2025 | 17.51% | Raymond James | $119 → $104 | Maintains | Outperform | |||
05/06/2025 | 29.94% | Stifel | $138 → $115 | Maintains | Buy | |||
05/06/2025 | 26.55% | RBC Capital | $125 → $112 | Maintains | Outperform | |||
05/06/2025 | 7.34% | Morgan Stanley | $115 → $95 | Maintains | Equal-Weight | |||
05/06/2025 | 18.64% | JP Morgan | $128 → $105 | Maintains | Overweight | |||
05/06/2025 | 10.73% | Wells Fargo | $113 → $98 | Maintains | Equal-Weight | |||
05/06/2025 | 29.94% | Baird | $130 → $115 | Maintains | Outperform | |||
02/10/2025 | 27.68% | Truist Securities | $118 → $113 | Reiterates | Hold → Hold | |||
02/10/2025 | 26.55% | Barclays | $118 → $112 | Maintains | Underweight | |||
02/07/2025 | 41.24% | RBC Capital | $130 → $125 | Maintains | Outperform | |||
02/07/2025 | 34.46% | Raymond James | $126 → $119 | Maintains | Outperform | |||
02/07/2025 | 58.19% | JMP Securities | $140 → $140 | Reiterates | Market Outperform → Market Outperform | |||
02/07/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/29/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/23/2025 | 55.93% | Stifel | $130 → $138 | Maintains | Buy | |||
12/18/2024 | 46.89% | RBC Capital | $125 → $130 | Maintains | Outperform | |||
12/18/2024 | 33.33% | Truist Securities | $117 → $118 | Maintains | Hold | |||
12/17/2024 | 44.63% | JP Morgan | $125 → $128 | Upgrade | Neutral → Overweight | |||
12/12/2024 | 33.33% | Barclays | $125 → $118 | Maintains | Underweight | |||
11/04/2024 | 41.24% | RBC Capital | $120 → $125 | Maintains | Outperform | |||
11/01/2024 | 32.2% | Truist Securities | $112 → $117 | Maintains | Hold | |||
10/31/2024 | 32.2% | Wells Fargo | $110 → $117 | Maintains | Equal-Weight | |||
10/31/2024 | — | Needham | — | Reiterates | → Hold | |||
10/15/2024 | 52.54% | Oppenheimer | $145 → $135 | Maintains | Outperform | |||
10/14/2024 | 38.98% | Raymond James | $128 → $123 | Maintains | Outperform | |||
10/08/2024 | 35.59% | RBC Capital | $130 → $120 | Maintains | Outperform | |||
10/03/2024 | 42.37% | BTIG | $134 → $126 | Maintains | Buy | |||
10/01/2024 | 24.29% | Evercore ISI Group | $113 → $110 | Maintains | In-Line | |||
09/17/2024 | — | Needham | — | Reiterates | → Hold | |||
09/16/2024 | 35.59% | JP Morgan | $125 → $120 | Maintains | Neutral | |||
09/13/2024 | 26.55% | Truist Securities | $117 → $112 | Reiterates | Hold → Hold | |||
09/10/2024 | 29.94% | Canaccord Genuity | $120 → $115 | Maintains | Hold | |||
09/10/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
09/06/2024 | 34.46% | TD Cowen | $143 → $119 | Maintains | Hold | |||
09/05/2024 | 32.2% | Truist Securities | $117 → $117 | Maintains | Hold | |||
09/05/2024 | 27.68% | Evercore ISI Group | $113 → $113 | Maintains | In-Line | |||
08/20/2024 | 35.59% | Canaccord Genuity | $130 → $120 | Maintains | Hold | |||
08/08/2024 | 46.89% | RBC Capital | $140 → $130 | Maintains | Outperform | |||
08/08/2024 | 44.63% | Raymond James | $138 → $128 | Maintains | Outperform | |||
08/08/2024 | 20.9% | UBS | $112 → $107 | Maintains | Sell | |||
08/08/2024 | 63.84% | Oppenheimer | $155 → $145 | Maintains | Outperform | |||
08/08/2024 | 27.68% | Evercore ISI Group | $115 → $113 | Maintains | In-Line | |||
08/08/2024 | 63.84% | Baird | $155 → $145 | Maintains | Outperform | |||
08/08/2024 | — | Needham | — | Reiterates | → Hold | |||
07/16/2024 | 32.2% | Truist Securities | $130 → $117 | Maintains | Hold | |||
07/15/2024 | 35.59% | Morgan Stanley | $130 → $120 | Maintains | Equal-Weight | |||
07/10/2024 | 35.59% | Citigroup | $134 → $120 | Maintains | Neutral | |||
07/02/2024 | 29.94% | Evercore ISI Group | $130 → $115 | Maintains | In-Line | |||
07/01/2024 | 29.94% | Piper Sandler | $140 → $115 | Downgrade | Overweight → Neutral | |||
05/31/2024 | 41.24% | Barclays | $130 → $125 | Maintains | Underweight | |||
05/30/2024 | 45.76% | Goldman Sachs | → $129 | Initiates | → Neutral | |||
05/30/2024 | — | Needham | — | Reiterates | → Hold | |||
05/21/2024 | 69.49% | Argus Research | → $150 | Upgrade | Hold → Buy | |||
05/17/2024 | — | Needham | — | Reiterates | → Hold | |||
05/03/2024 | 46.89% | Truist Securities | $137 → $130 | Maintains | Hold | |||
05/03/2024 | 75.14% | Oppenheimer | $150 → $155 | Maintains | Outperform | |||
05/02/2024 | — | Needham | — | Reiterates | → Hold | |||
04/04/2024 | 46.89% | Evercore ISI Group | $125 → $130 | Maintains | In-Line | |||
04/03/2024 | 58.19% | Citigroup | $134 → $140 | Maintains | Neutral | |||
02/23/2024 | 46.89% | Canaccord Genuity | → $130 | Reiterates | Hold → Hold | |||
02/12/2024 | 46.89% | Barclays | $120 → $130 | Maintains | Underweight | |||
02/09/2024 | 58.19% | RBC Capital | $140 → $140 | Reiterates | Outperform → Outperform | |||
02/09/2024 | 52.54% | Truist Securities | $133 → $135 | Maintains | Hold | |||
02/09/2024 | 41.24% | JP Morgan | $115 → $125 | Maintains | Neutral | |||
01/12/2024 | 58.19% | RBC Capital | $134 → $140 | Maintains | Outperform | |||
01/04/2024 | 41.24% | Evercore ISI Group | $135 → $125 | Downgrade | Outperform → In-Line | |||
01/03/2024 | 54.8% | Raymond James | $133 → $137 | Maintains | Outperform | |||
12/22/2023 | 50.28% | Truist Securities | $115 → $133 | Maintains | Hold | |||
12/04/2023 | 41.24% | Morgan Stanley | $120 → $125 | Maintains | Equal-Weight | |||
11/13/2023 | 58.19% | JMP Securities | $160 → $140 | Maintains | Market Outperform | |||
11/09/2023 | 50.28% | Raymond James | $160 → $133 | Maintains | Outperform | |||
11/08/2023 | 35.59% | Morgan Stanley | $140 → $120 | Maintains | Equal-Weight | |||
11/08/2023 | 29.94% | JP Morgan | $146 → $115 | Maintains | Neutral | |||
10/20/2023 | 35.59% | Roth MKM | → $120 | Initiates | → Neutral | |||
10/02/2023 | 41.24% | Citigroup | $146 → $125 | Maintains | Neutral | |||
08/28/2023 | 57.06% | BTIG | → $139 | Upgrade | Neutral → Buy | |||
08/02/2023 | 67.23% | Truist Securities | $153 → $148 | Maintains | Hold | |||
08/02/2023 | 58.19% | Morgan Stanley | $140 → $140 | Reiterates | Equal-Weight → Equal-Weight | |||
08/02/2023 | 80.79% | JMP Securities | → $160 | Reiterates | Market Outperform → Market Outperform | |||
08/02/2023 | 77.4% | Oppenheimer | → $157 | Reiterates | Outperform → Outperform | |||
08/02/2023 | 35.59% | Barclays | $116 → $120 | Maintains | Underweight | |||
07/19/2023 | 72.88% | Truist Securities | $147 → $153 | Maintains | Hold |
FAQ
Quel est le cours indicatif de l'action Zimmer Biomet Holdings (ZBH) ?
Le dernier objectif de prix pour Zimmer Biomet Holdings (NYSE:ZBH) a été rapporté par UBS le novembre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $88.00 s'attendant à ce que ZBH se fall dans les 12 prochains mois (un possible changement de -0.56% downside). 37 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Zimmer Biomet Holdings (ZBH) ?
La dernière note d'analyste pour Zimmer Biomet Holdings (NYSE:ZBH) a été fournie par UBS, et Zimmer Biomet Holdings maintenu leur note sell.
Quand a eu lieu la dernière mise à niveau pour Zimmer Biomet Holdings (ZBH) ?
La dernière amélioration pour Zimmer Biomet Holdings Inc a eu lieu le décembre 17, 2024 lorsque JP Morgan a augmenté leur objectif de prix à $128. JP Morgan avait précédemment a neutral pour Zimmer Biomet Holdings Inc.
Quand a eu lieu la dernière dégradation pour Zimmer Biomet Holdings (ZBH) ?
La dernière réduction pour Zimmer Biomet Holdings Inc a eu lieu le novembre 6, 2025 lorsque JP Morgan a changé leur objectif de prix de $115 à $100 pour Zimmer Biomet Holdings Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Zimmer Biomet Holdings (ZBH) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Zimmer Biomet Holdings, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Zimmer Biomet Holdings a été déposée le novembre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 6, 2026.
La note d'analyste pour Zimmer Biomet Holdings (ZBH) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Zimmer Biomet Holdings (ZBH) était un maintenu avec un objectif de prix de $96.00 à $88.00. Le prix actuel de Zimmer Biomet Holdings (ZBH) est de $88.50, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.